NIH Funding Opportunities

Notice of NIAAA's Participation in PAR-19-246 "Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Abuse and Addiction Scientists (R25 - Clinical Trials Not Allowed)
Notice NOT-AA-19-015 from the NIH Guide for Grants and Contracts
Tue, 21 May 2019 12:16:58 EST

Notice of Intent to Publish a Funding Opportunity Announcement for Consortium on the Neurobiology of Adolescent Drinking in Adulthood (NADIA) Research Projects (U01) (Clinical Trial Not Allowed)
Notice NOT-AA-19-016 from the NIH Guide for Grants and Contracts
Wed, 22 May 2019 12:57:16 EST

Notice of Intent to Publish a Funding Opportunity Announcement for Consortium on the Neurobiology of Adolescent Drinking in Adulthood (NADIA) Administrative Resource (U24) (Clinical Trial Not Allowed)
Notice NOT-AA-19-017 from the NIH Guide for Grants and Contracts
Wed, 22 May 2019 12:57:07 EST

Notice of Intent to Publish a Funding Opportunity Announcement for Consortium on the Neurobiology of Adolescent Drinking in Adulthood (NADIA) Research Resource (U24) (Clinical Trial Not Allowed)
Notice NOT-AA-19-018 from the NIH Guide for Grants and Contracts
Wed, 22 May 2019 12:57:11 EST

Notice of Participation of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) in PAR-19-093, Leveraging Health Information Technology (Health IT) to Address Minority Health and Health Disparities (R01 Clinical Trial Optional)
Notice NOT-AA-19-019 from the NIH Guide for Grants and Contracts
Wed, 22 May 2019 01:52:41 EST

Notice of Change to Application Types Allowed for PAR-18-767 "Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (Collaborative U54 Clinical Trial Optional)"
Notice NOT-CA-19-052 from the NIH Guide for Grants and Contracts
Wed, 22 May 2019 09:19:22 EST

Notice of Correction to PAR-19-246 "Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Abuse and Addiction Scientists (R25 - Clinical Trials Not Allowed)"
Notice NOT-DA-19-044 from the NIH Guide for Grants and Contracts
Tue, 21 May 2019 12:09:03 EST

Notice to Extend the Expiration Date of PAR-18-084 "Integrative Research on Polysubstance Abuse and Addiction (R21/R33 Clinical Trial Optional)"
Notice NOT-DA-19-045 from the NIH Guide for Grants and Contracts
Wed, 22 May 2019 09:01:12 EST

Notice of Webinar for RFA-DA-20-017 and RFA-DA-20-018, "Digital Health Technologies to Address the Social Determinants of Health in context of Substance Use Disorders (SUD)
Notice NOT-DA-19-046 from the NIH Guide for Grants and Contracts
Mon, 20 May 2019 09:14:17 EST

Notice of Intent to Publish a Funding Opportunity Announcement for The National Drug Abuse Treatment Clinical Trials Network (UG1) Clinical Trial Optional
Notice NOT-DA-19-047 from the NIH Guide for Grants and Contracts
Wed, 22 May 2019 01:46:01 EST

Notice of Special Interest (NOSI): Understanding Factors in Infancy and Early Childhood (Birth to 24 months) That Influence Obesity Development
Notice NOT-HL-19-695 from the NIH Guide for Grants and Contracts
Tue, 21 May 2019 11:55:20 EST

Notice of Intent to Publish the Reissuance of "Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3 Clinical Trial Required)"
Notice NOT-HL-19-700 from the NIH Guide for Grants and Contracts
Wed, 22 May 2019 08:31:26 EST

Required Use of the xTRACT System to Prepare Data Tables for Training Grant Research Performance Progress Reports in FY 2020
Notice NOT-OD-19-108 from the NIH Guide for Grants and Contracts
Tue, 21 May 2019 11:36:21 EST

Understanding Senescence in Brain Aging and Alzheimer's Disease (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AG-20-025 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to support research focused on understanding the role of senescence in brain aging and in Alzheimer's disease (AD). This FOA encourages research projects addressing critical knowledge gaps in our understanding of the neurobiology of senescence through cutting-edge techniques, cross-disciplinary collaborations, and/or conceptual innovation, leveraging what is known about senescence in peripheral tissues to learn more about brain aging. Developing a clear understanding of the mechanisms driving aging processes in the brain, including senescence, is essential for combating age-related neurodegenerative diseases.
Thu, 23 May 2019 02:22:45 EST

SCAN: Standardized Centralized Alzheimer's and Related Dementias Neuroimaging (U24 Clinical Trials Not Allowed)
Funding Opportunity RFA-AG-20-043 from the NIH Guide for Grants and Contracts. This funding opportunity will support a new, centralized infrastructure (U24) to aggregate, harmonize, manage, and share existing and future neuroimaging data collected in NIA- supported Alzheimer's Disease Research Centers (ADRCs).
Wed, 22 May 2019 02:53:33 EST

Workshops on the Use of Adolescent Brain Cognitive Development (ABCD) Data (R25 Clinical Trial Not Allowed)
Funding Opportunity RFA-DA-20-001 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIDA/NIMH R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs in the use of ABCD data. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on courses for skills development, particularly short-term workshops that will allow participants to explore the hands-on use of ABCD data, through cooperative or competitive approaches.
Wed, 22 May 2019 02:11:37 EST

Methods to Improve Reproducibility of Human iPSC Derivation, Growth and Differentiation (SBIR) (R44 Clinical Trial Not Allowed)
Funding Opportunity RFA-GM-19-001 from the NIH Guide for Grants and Contracts. Human induced pluripotent stem cells (iPSCs) have been used with great success to mimic the differentiation of a variety of tissues, understand early development and study human diseases. Despite approaches that have made the derivation, growth and differentiation of iPSCs more efficient, there remains significant variability in reprogramming efficacy, genomic integrity and developmental potential of iPSCs derived from a single fibroblast or tissue sample. Thus, iPSCs derived from the same sample may differ in their in vitro growth characteristics and their ability to re-differentiate into the desired tissue type. A variety of issues may affect derivation of the iPSCs and their growth, stability and differentiation, including the specific characteristics of the starting cell or tissue sample (e.g., age of donor, tissue type and anatomical location, physiological and disease state), the methods and protocols used to induce pluripotency (e.g., transcription factors, small molecules, cell fusion), the choice of growth factors and other culture conditions, method of storage of cell lines, etc. Further challenges include growing and maintaining sufficient quantities of iPSC lines in culture without changes in their properties, as well as the ability of multiple investigators to identify and authenticate iPSC lines as part of their research. This Funding Opportunity Announcement (FOA) will support SBIR projects to develop novel, reliable and cost-effective methods to standardize and increase the utility and reproducibility of iPSCs at all stages, from their derivation to their research and clinical applications.
Tue, 21 May 2019 11:42:52 EST

The Electronic Medical Records and Genomics (eMERGE): Genomic Risk Assessment and Management Network - Clinical Sites (U01 Clinical Trial Required)
Funding Opportunity RFA-HG-19-013 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to participate in the Electronic Medical Records and Genomics (eMERGE) Genomic Risk Assessment and Management Network. This network will continue to use biorepositories linked with electronic medical records (EMRs) for genomic research by developing, evaluating, and disseminating genomic risk assessment and management tools for clinical use. Applicants to this FOA are expected to recruit a minimum of 35% of patients who come from racial or ethnic minority populations, underserved populations, or populations who experience poorer medical outcomes. In contrast, applicants to the companion RFA-HG-19-014 are expected to recruit a minimum of 75% of such patients.
Thu, 23 May 2019 11:54:54 EST

The Electronic Medical Records and Genomics (eMERGE): Genomic Risk Assessment and Management Network - Enhanced Diversity Clinical Sites (U01 Clinical Trial Required)
Funding Opportunity RFA-HG-19-014 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to participate in the Electronic Medical Records and Genomics (eMERGE) Genomic Risk Assessment and Management Network. This network will continue to use biorepositories linked with electronic medical records (EMRs) for genomic research by developing, evaluating, and disseminating genomic risk assessment and management tools for clinical use. Applicants to this FOA are expected to recruit a minimum of 75% of patients who come from racial or ethnic minority populations, underserved populations, or populations who experience poorer medical outcomes. In contrast, applicants to the companion RFA-HG-19-013 are expected to recruit a minimum of 35% of such patients.
Thu, 23 May 2019 11:54:52 EST

The Electronic Medical Records and Genomics (eMERGE): Genomic Risk Assessment and Management Network - Coordinating Center (U01 Clinical Trial Required)
Funding Opportunity RFA-HG-19-015 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to continue genomic implementation research in the Electronic Medical Records and Genomics (eMERGE) Network by providing support for a Coordinating Center (CC) to provide centralized support, infrastructure, coordination, and data analysis for the program.
Thu, 23 May 2019 11:54:51 EST

Drug Screening with Biofabricated 3-D Skin Disease Tissue Models (U18 Clinical Trial Not Allowed)
Funding Opportunity RFA-TR-19-020 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to build upon the work that has begun under previous FOA RFA-TR-17-007 NCATS Pilot Program for Collaborative Drug Discovery Research Using Bioprinted Skin Tissue and utilize physiologically relevant and validated 3-D biofabricated skin disease tissue models in multi-well drug screening platforms. The FOA will support intramural- extramural collaborations to implement the use of 3-D biofabricated skin tissue models and provide evidence of success for 3-D drug screening platforms.
Tue, 21 May 2019 02:19:47 EST

Postdoctoral Research Associate Training (PRAT) Program (Fi2)
Funding Opportunity PAR-19-286 from the NIH Guide for Grants and Contracts. The NIGMS Postdoctoral Research Associate Training (PRAT) Programs overarching goal is to provide high quality postdoctoral research training in the basic biomedical sciences to a diverse group of postdoctoral fellows in NIH Intramural research laboratories, and to prepare them for leadership positions in biomedical careers. Research projects proposed should focus on areas within the NIGMS mission, which include but are not limited to biological chemistry, biophysics, bioinformatics, cellular and molecular biology, computational biosciences, developmental biology, genetics, immunology, neuroscience, pharmacology, physiology, and technology development. In addition to the laboratory experience, the PRAT program provides a structured training environment with extensive career and professional development, mentoring, and networking opportunities planned and supported by the program.
Tue, 21 May 2019 01:40:59 EST

Research Projects in Cancer Systems Biology (U01 Clinical Trial Optional)
Funding Opportunity PAR-19-287 from the NIH Guide for Grants and Contracts. The National Cancer Institutes (NCI) Cancer Systems Biology Consortium (CSBC) supports systems biology approaches to cancer research and includes U54 CSBC Research Centers, a U24 CSBC Coordinating Center and, through this FOA, well-defined, discrete and circumscribed U01 Research Projects. CSBC Research Projects are expected to involve interdisciplinary teams of scientists, engineers, and cancer researchers who collaborate to advance our understanding of the mechanisms underlying cancer initiation, progression, and treatment. CSBC Research Projects proposed in response to this Funding Opportunity Announcement must demonstrate explicit integration of experimental biology and computational modeling to test and validate novel hypotheses in cancer research.
Wed, 22 May 2019 03:09:11 EST

Limited Competition: NIA Genome Center for Alzheimer's Disease (U54 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-288 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to continue the operations of the NIA Genome Center for Alzheimer's Disease (GCAD) to facilitate and support the Alzheimer's Disease Sequencing Project (ADSP) activities. GCAD will serve as the focal point for all phases of ADSP quality control checking, data harmonization, and meta-analysis. The FOA is intended to support a major component of the full range of analysis for the ADSP. The spectrum of the Center's activities comprises a multidisciplinary attack on Alzheimer's Disease (AD) and AD Related Dementias (ADRD) in keeping with NIA's programmatic needs. The Center will serve as a national resource for the specific purpose of identifying potential avenues for therapeutic approaches and prevention of the disease.
Thu, 23 May 2019 01:00:22 EST